2-[(2,6-二吡咯烷-1-基嘧啶-4-基)氨基]-1-吡咯烷-1-基乙酮 | 331268-13-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-[(2,6-二吡咯烷-1-基嘧啶-4-基)氨基]-1-吡咯烷-1-基乙酮
• 英文名称: 2-{[2,6-Di(pyrrolidin-1-yl)pyrimidin-4-yl]amino}-1-(pyrrolidin-1-yl)ethan-1-one
• 英文别名: 2-[(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)amino]-1-pyrrolidin-1-ylethanone
• CAS: 331268-13-4
• 化学式: C₁₈H₂₈N₆O
• 分子量: 344.46
• InChiKey: KVRJGCYXXUCVBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-[(2,6-二吡咯烷-1-基嘧啶-4-基)氨基]-1-吡咯烷-1-基乙酮 在 5%-palladium/activated carbon 、 三乙胺 、 calcium chloride 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 、 乙腈 为溶剂， 反应 16.0h， 生成 2-(2,4-Di-1-pyrrolidinyl-9H-pyrimido(4,5-b)indol-9-yl)-1-(1-pyrrolidinyl)ethanone
  参考文献：
  名称：

  Synthesis of 2,4-Di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indoles, Including Antiasthma Clinical Candidate PNU-142731A

  摘要：

  Two syntheses are described for 1-[(2,4.di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indol-9-yl)-acetyl]pyrrolidine hydrochloride (PNU-142731A), a clinical candidate in the asthma area. The route involving the initial regioselective addition of glycine ethyl ester to commercially available 2,4,6-trichloropyrimidine is particularly well suited for large-scale operation, as it is short, proceeds in good yield, is operationally straightforward, and requires no chromatographic purification of intermediates.

  DOI：

  10.1021/op000221p
• 作为产物：
  描述：

  四氢吡咯 、 2,4,6-三氯嘧啶 、 甘氨酸乙酯盐酸盐 在 N,N-二异丙基乙胺 作用下， 以 乙酸乙酯 、 甲醇 为溶剂， 生成 2-[(2,6-二吡咯烷-1-基嘧啶-4-基)氨基]-1-吡咯烷-1-基乙酮 、 、
  参考文献：
  名称：

  Synthesis of 2,4-Di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indoles, Including Antiasthma Clinical Candidate PNU-142731A

  摘要：

  Two syntheses are described for 1-[(2,4.di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indol-9-yl)-acetyl]pyrrolidine hydrochloride (PNU-142731A), a clinical candidate in the asthma area. The route involving the initial regioselective addition of glycine ethyl ester to commercially available 2,4,6-trichloropyrimidine is particularly well suited for large-scale operation, as it is short, proceeds in good yield, is operationally straightforward, and requires no chromatographic purification of intermediates.

  DOI：

  10.1021/op000221p

文献信息

• Synthesis of 2,4-Di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indoles, Including Antiasthma Clinical Candidate PNU-142731A
  作者：Gordon L. Bundy、Lee S. Banitt、Paul J. Dobrowolski、John R. Palmer、Theresa M. Schwartz、David C. Zimmermann、Michael F. Lipton、Michael A. Mauragis、Michael F. Veley、Robert B. Appell、Robert C. Clouse、Edward D. Daugs

  DOI：10.1021/op000221p

  日期：2001.3.1

  Two syntheses are described for 1-[(2,4.di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indol-9-yl)-acetyl]pyrrolidine hydrochloride (PNU-142731A), a clinical candidate in the asthma area. The route involving the initial regioselective addition of glycine ethyl ester to commercially available 2,4,6-trichloropyrimidine is particularly well suited for large-scale operation, as it is short, proceeds in good yield, is operationally straightforward, and requires no chromatographic purification of intermediates.